For example, a peptide-based vaccine plus poly-ICLC for low-grade gliomas using four targets (IL-13RA2, EphA2 receptor, Wilms tumor 1 and survivin) was well tolerated in patients with grade II glioma [50]. This evidence concerns the gene IL13RA2 and central nervous system cancer.